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Abstract
Background: Intranasal olfactory drug delivery provides a non-invasive method that bypasses the Blood-Brain-Barrier and
directly delivers medication to the brain and spinal cord. However, a device designed specifically for olfactory delivery has
not yet been found.
Methods: In this study, a new delivery method was proposed that utilized electrophoretic forces to guide drug particles to
the olfactory region. The feasibility of this method was numerically evaluated in both idealized 2-D and anatomically
accurate 3-D nose models. The influence of nasal airflow, electrode strength, and drug release position were also studied on
the olfactory delivery efficiency.
Findings: Results showed that by applying electrophoretic forces, the dosage to the olfactory region was significantly
enhanced. In both 2-D and 3-D cases, electrophoretic-guided delivery achieved olfactory dosages nearly two orders of
magnitude higher than that without electrophoretic forces. Furthermore, releasing drugs into the upper half of the nostril
(i.e., partial release) led to olfactory dosages two times higher than releasing drugs over the entire area of the nostril. By
combining the advantages of pointed drug release and appropriate electrophoretic guidance, olfactory dosages of more
than 90% were observed as compared to the extremely low olfactory dosage (,1%) with conventional inhaler devices.
Conclusion: Results of this study have important implications in developing personalized olfactory delivery protocols for the
treatment of neurological disorders. Moreover, a high sensitivity of olfactory dosage was observed in relation to different
pointed release positions, indicating the importance of precise particle guidance for effective olfactory delivery.
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metered-dosed inhaler (pMDI), devices designed for olfactory
deposition have not yet been found [7]. The limitations of
conventional nasal devices are obvious; only a very small fraction
of therapeutic agents deposit in the olfactory region and enter the
brain. Previous studies [8,9] have shown that less than 1% of
nasal-inhaled particles could reach the olfactory nerves which are
secluded in the upmost part of the nasal cavity (Fig. 1a). Therefore,
it is critical to search for more effective methods to deliver drugs to
the olfactory region.
The low olfactory delivery efficiency is mainly attributed to the
unique structure of the human nasal cavity, which consists of two
relatively symmetric nasal passages separated by a nasal septum.
Each nasal passage has three curved fin-like airway protrusions
known as the superior, middle and inferior meatus. The osseous
tissues above each meatus are termed the superior, middle, and
inferior turbinates, respectively, and form the lateral wall of the
main passage. The olfactory epithelium, or olfactory mucosa, is
located at the very top of the nasal cavity between the superior
turbinate and the cribriform plate of the ethmoid bone (Figs. 1a)
and covers 10,12 cm2, or approximately 8% of the total nasal

Introduction
The Blood-Brain-Barrier (BBB) has forestalled the use of many
new genetically engineered drugs for treating central nervous
system (CNS) disorders such as Alzheimer’s disease [1], paraplegia
[2], and migraine headache [3]. The need for developing a simple,
safe, and effective way of delivering drugs for the treatment of
CNS disorders is urgent. The olfactory region is the only site in the
human body where the CNS is in direct contact with the outer
environment. If drugs could be directly sent to this region through
the nose, they can diffuse through the olfactory mucosa and reach
the CNS via the extracellular epithelial pathway [4]. Direct noseto-brain drug delivery circumvents the BBB and has multiple
advantages over conventional intravenous delivery methods.
These advantages include ease of administration, rapid onset of
action, and avoidance of first-pass metabolism [5,6]. However,
demonstration of its clinical feasibility is still in adolescence due to
a lack of devices that effectively deliver medication to the olfactory
region. While there are many nasal delivery devices available on
the market such as a nebulizer, powder inhaler, or pressurized
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Figure 1. Nasal airway anatomy with the olfactory region (OR). Geometric complexity and narrowness of the nasal airway prevents effective
intranasal drug delivery. To avoid contact loss to the wall, particles should closely follow the middle plane (a) of the nasal passage, which exhibits
three-dimensional spatial features. A simple delivery system is shown in (b) which consists of components with the following four functions: (1)
aerosol generation (inhaler), (2) particle charging, (3) particle focusing, and (4) particle navigation control. A more elaborate system can have supports
to stabilize the device relative to the human head.
doi:10.1371/journal.pone.0086593.g001

carefully arranging multiple electrodes with different electric
potentials around the nose.
Charged particles have found their way into many industrial
and medical applications, such as ink jet printing, electrostatic
precipitation, and mass spectrometry. The sizing, classification,
and collection of nanoparticles primarily depends on their
electrical properties [13]. In light of inhaled charge particles, a
number of theoretical and experimental studies have considered
the transport and deposition of charged particles in human
respiratory tract [14,15,16,17,18,19,20,21]. By gradually reducing
the particle charges in a nasal replica cast, Fry [19] reported that
partially neutralized particles and Boltzmann charged particles
had similar deposition characteristics in the nasal cavity. However,
the charge levels in this study are well below those typical of
metered dose inhalers that are sufficiently high to alter deposition
of inhaled particles in the respiratory tract [17]. Boltzmann charge
on submicron aerosols can be significant [13] and may cause some
level of deposition variations that were not identified by Fry [19].
Considerable deposition enhancement has been reported in the
larynx and tracheobronchial cast for both micrometer [14] and
submicron [15] charged particles, even in the absence of an
external electric field. Yu and coworkers [18,22] theoretically
studied the electrostatic precipitation in pipe flows with specified
electric potentials and proposed empirical correlations for charged
aerosol depositions in such idealized geometries. However, these
correlations, which were based on fully developed flows, cannot be
readily extended to complex geometries such as the respiratory
tract where developing flow prevails.
The objectives of this study are to (1) develop a computational
fluid dynamics (CFD) model of electrophoretic-guided drug
delivery; (2) numerically evaluate the feasibility of electrophoretic
focusing in three quadrupole designs; (3) numerically evaluate the
efficiency of the electrophoretic-guided drug delivery in both
idealized 2-D and physiologically realistic 3-D nose models; and (4)
identify the optimal layout and operating parameters of the

surface area [10]. If drugs can be delivered deep and high enough
into the nasal cavity, they will reach the olfactory mucosa and
enter the brain. However, the intricacy of the nasal geometry
prevents effective intranasal drug delivery. The particle motions
are highly complex and far from planar, as shown in Fig. 1a. Most
of the inhaled particles will impinge on the nasal walls and be
filtered out. Conventional inhalation drug delivery devices depend
solely on inhalation aerodynamics to direct drug particles to the
target site [11]. The three major forces acting on these particles
are inertia, drag force, and gravity. There is no further control on
the trajectories of these particles once they have been released
from an inhalation device. Accordingly, how far a particle travels,
or where it deposits primarily depends on its initial velocity as well
as the nasal airway structure. Due to this lack of control, a
significant amount of medication is wasted in the upper airway
and cannot reach the targeted olfactory receptor.
The rationale of electrophoretic drug delivery can be compared
to that of guided ballistic missiles. The missiles can precisely hit
their targets because they are under continuous control along
specified trajectories. Similarly, it would be highly desirable if we
could control the pharmaceutical particles so that they behave
much like guided missiles. This seems challenging considering the
tiny size of these aerosols (0.2–5 microns) and the complex nasal
structure, which requires extreme accuracy to navigate the
particles through the convoluted conchae and toward the hidden
olfactory region. Interestingly, the solution to this problem lies in
the problem itself, or the tiny particle size. Electrophoretic force on
nanoparticles can be dominate, which make it possible to remotely
control inhaled aerosols. The smaller the size of the particles, the
more they are influenced by the electromagnetic force [12]. It is
hypothesized that with an appropriate external electric field,
charged nanoparticles can be precisely guided via electrophoretic
forces and maneuvered through the nasal passages without loss to
the airway walls. The required electric field can be achieved by
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electrodes. Potential benefits from this study include (1) insight into
the transport dynamics underlying the delivery of intranasal
neurological medications and (2) guidelines for the development of
effective drug delivery devices that target the olfactory epithelium.

Fluid-Particle Transport Models
Flows in this study were assumed to be isothermal and
incompressible. Steady inhalation and normal breathing conditions was assumed for all simulations. The mean inlet Reynolds
number at the nostrils was around 1,413 [31]. The flow conditions
inside the human nasal airways are predominately laminar flows.
Therefore, the laminar flow model has been adopted in this study.
The trajectories of monodispersed particles with diameters (dp)
were calculated on a Lagrangian basis by directly integrating an
appropriate form of the particle transport equation. A smaller
particle has a smaller inertia, a larger diffusion, and a larger
influence from the electrophoretic force. The particles considered
in this study were 0.5 mm in diameter because of their relatively
small inertial and diffusive properties while maintaining a
relatively large electrophoretic force. Aerosols of this size range
have very low Stokes numbers (Stk = rpdp2UCc/18 mDh,,1),
where rp is the particle density (1.0 g/cm3), Cc the Cunningham
slip correction factor, m the fluid viscosity, U the mean fluid
velocity, and Dh the hydraulic diameter of the nostril. The
governing equation for spherical particle motion under these
conditions can be expressed as [32],

Methods
Nasal Airway Model
A physiologically accurate airway model is necessary for reliable
analysis of inhalation drug delivery. Image-based modeling
represents a remarkable improvement over conventional cadaver
castings that are subject to large distortions due to the shrinkage of
mucous membranes or insertion of casting materials. MRI scans of
a healthy non-smoking 53-year-old male (weight 73 kg and height
173 cm) were used in this study to construct the nasal airway
model (Fig. 1a). The MRI tracings were provided by the Hamner
Institutes for Health Sciences (Research Triangle Park, NC), the
use of which has been approved by the Virginia Commonwealth
University Institutional Review Board. This MRI dataset was
originally reported by Guilmette et al. [23] in 1989 and has been
implemented in a number of nasal particle deposition experiments
[24,25] and simulations [26,27]. The multi-slice MRI scans were
first segmented using MIMICS (Materialise, Ann Arbor, MI) into
a 3-D model, which was further converted into a set of contours
that defined the airways of interest. Based on these contours, an
internal surface geometry was constructed in Gambit 2.4. The
resulting model is intended to accurately represent the anatomy of
the nasal airway with only minor surface smoothing. This model
can either be manufactured into a solid cast by prototyping
techniques for in vitro studies, or be meshed with high-quality
computational elements for numerical analysis.

dvi
f
~
ðui {vi Þzgi ð1{aÞzfi, Brownian
tp Cc
dt

ð1Þ

zfi, lift zfi, electrophoretic
where vi is the particle velocity, ui is the local fluid velocity, and tp
(i.e., rp dp2/18 m) is the characteristic time required for a particle
to respond to changes in the flow field. The drag factor f, which
represents the ratio of the drag coefficient CD to Stokes drag, is
based on the expression of Morsi and Alexander [33] for aerosols
greater than 1 mm. Non-continuum slip effects on the drag of
nanoparticles are accounted for using the Cunningham correction
(Cc) factor [13]. The gravity force was included with the gravity
vector oriented in the vertical direction. The Saffman lift force was
calculated for particles greater than 1 mm [34]. The effect of
Brownian motion was considered for particles less than 1 mm [35].
One-way flow-particle coupling was implemented in this study
because of the diluted concentration of drug aerosols. The
computational fluid-particle dynamics model used in this study
has been validated against existing experimental data in comparable airway models [36,37]. The numerically determined
deposition results agreed with experimental data within 5% for
both sedentary (15 L/min) and light activity (30 L/min) inhalation
conditions, indicating that the model hereof was adequate to
capture the physical realism of interest.

Electrophoretic Olfactory Delivery Protocol
A simple device of such delivery protocol will consist of
components with the following four functions: (a) aerosol
generation (inhaler), (b) particle charging, (c) particle focusing,
and (d) particle navigation control (Fig. 1b). More elaborate
devices can add supports to stabilize the device relative to the
human head. Particles are to be generated using available inhaler
devices such as a nebulizer, pMDI, and dry powder inhaler [28].
The particles then pass through a charging chamber and acquire a
given number of charges (usually positively charges) [29]. The
positively charged particles subsequently enter the focusing
chamber that has multiple slits [30]. The first slit has a high
positive voltage and the last one has zero voltage. As the particles
pass through the slits, the inward repulsive force drives the aerosol
into a finely focused beam; meanwhile the forward repulsive force
accelerates the particle beam to a certain exit speed (or inlet speed
into the nostrils). The advantage of knowing the nasal inlet speed is
that the particle trajectory can be predetermined for a given
release point. Yet another advantage is that the speed of an aerosol
could be much higher than the inhaled air speed so that it does not
rely on inhalation maneuvers, making it suitable for seniors or
patients with respiration difficulties. Once entering the nasal
cavity, the particles are subjected to the electrophoretic force and
begin to deviate from their original trajectories in a controlled
manner (i.e., particle guidance). A precise control of the path
deviations will guide the particles to the targeted olfactory receptor
with minimal loss to the nasal valves and turbinates. In this study,
we will limit our attention to the feasibility of electrophoretic
guidance of neurological drug particles with electric potentials and
charge levels that are safe to the human body.

Electric Field and Electrophoretic Force
For the DC field, the electric potential, UDC, is obtained by
solving Poisson’s equation,
{+:e0 er +U~0

ð2Þ

where e0 is the permittivity of free space (F/m) and er is the relative
permittivity of free space. The zero on the right hand side of the
above equation indicates that the space charge density is
negligible. For the AC field, the conservation of electric currents
is solved to compute the AC potential, V [38]:
{+:ðszjve0 er Þ+V ~0

ð3Þ

where s is the electrical conductivity and v is the angular
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frequency (Hz). The total electric field is obtained from the
superposition of the DC and AC fields considering that the
equations for DC and AC fields are linear.
The electrophoretic force is computed by
fi, electrophoretic ~neE~neðEDC zEAC Þ

Results
Particle Focusing and Guidance in a Quadrupole Model
The feasibility of electrophoretic focusing and guidance was first
tested in a quadrupole geometry (Fig. 2), in which the trajectory of
charged particles can be manipulated by varying the electrode
arrangements. In this application, the applied voltage was 12 V
and the particle size was 0.5 mm with 200 elementary charges. The
inlet velocity of the airflow and charged particles was 0.1 m/s. The
electric field and particle trajectories in the quadrupole geometry
are shown in Fig. 2 for three test cases with different electrode
layouts. In the first trial, we tested the sensitivity of charged
nanoparticles to the electrophoretic guidance by varying the
electric fields in both direction and strength. In doing so, eight
groups of electrodes were arranged along the curve so that
different voltage combinations can be specified. In Fig. 2a, the two
opposite electrodes had the same voltage (12 V or 212 V).
Similarly, a zero electric field was achieved along the curved
centerline. The particles were concentrated within this field and at
the same time were guided toward the exit, maneuvering through
the curvatures by overcoming the inertial force.
In the second trial (Fig. 2b), we removed the voltage from the
last two electrode groups to verify the indispensability of
electrophoretic forces in particle focusing and navigation. As
expected, without electrophoretic forces, particle trajectories
departed from the centerline, indicating a break of force balance
between the electrophoretic and inertial forces. A careful
inspection of Figs. 3a&b further revealed this delicate force
balance, which was manifested in the wavelets or fluctuations of
particle trajectories along the curved centerline.
The third trial tested the capacity of electrophoretic forces in
modifying particle trajectories by adjusting the electrode layout
and/or strength (Fig. 2c). In this test, the two opposite electrodes in
the same group had different voltages (12 V, 6 V), with the two
neighboring groups alternating the voltage arrangement, as shown
in Fig. 2c. It was observed that the particle trajectories were indeed
modified, which largely followed the resultant zero-E field. This is
desirable because it provides a promising tool in guiding the drug
particles through convoluted nasal passages and navigating them
away from the nasal turbinates. A possible disadvantage of this
method is that the level particle focusing might be compromised,
as shown by the more erratic and dispersive particle traces in
Fig. 2c.

ð4Þ

Where n is the dimensionless charge number and e is the
elementary charge (e = 1.6610219 C), EDC and EAC are electric
field intensity which are computed as follows.
EDC ~{+U;

~ e(jvt) 
EAC ~{real½+V

ð5Þ

~ denotes that the AC electric potential is a
The symbol V
complex value. In this study, only voltages less than 12 V were
tested, which fell well within the human safety range (,50V) [39].
The corresponding operating parameters such as optimal particle
size, particle charge, drug release velocity/position, and electrode
layout/strength will be systematically explored, as described
below.
The relation between the applied voltage parameters and
particle path will be first explored in a quadrupole geometry. For
given particle paths, the required voltage parameters will be
calculated. These parameters will then be implemented in the twodimensional (2-D) and 3-D nose models to calculate the particle
trajectories. Considering the multiphysics involved and the
prolonged computational expenses incurred, use of a 2-D model
dramatically reduces computational times relative to 3-D modeling. It also allows us to reduce the model complexity without
diminishing its integrity, gain understanding of fundamental
physics underlying the transport process, and fine-tune the
operating parameters to be used in the more intricate 3-D models.
In this study, the influence of nasal airflow, electrode strength and
drug release position will be studied on the olfactory deposition.
The performance of the proposed delivery protocol will be
evaluated by comparing particle transport and deposition between
cases with and without electrophoretic guidance, as well as cases
with and without particle focusing (pointed release).

Numerical Method and Grid Sensitivity Analysis
To solve the metaphysics involved in this study, Comsol
(Burlington, MA) was used to simulate the relevant multiphysics
that include airflow, electric force, and particle tracing. Convergence of the flow field solution was assumed when the global mass
residual was reduced by four orders of magnitude and the residualreduction-rates for both mass and momentum were sufficiently
small. The computational mesh was generated in Comsol in multidomains with a physics-controlled manner. The nasal airway was
discretized based on fluid physics, and the remaining domains
(electrodes and open space) were based on general physics. To
resolve the possible steep gradients of flow variables in the nearwall region, body-fitted mesh was also utilized. In light of the high
complexity of nose morphology, corner mesh refinement was
implemented throughout the model geometry. A grid sensitivity
analysis was conducted by testing the effects of different mesh
densities with approximately 0.4 million, 0.790 million, 1.1
million, and 2.0 million elements (degrees of freedoms). The
predicted deposition rate was less than 1% when increasing mesh
size from 1.1 million to 2.0 million. As a result, the final grid for
reporting flow field and deposition conditions consisted of
approximately 1.1 million cells.
PLOS ONE | www.plosone.org

Two-dimensional Nose Model
The feasibility of the new delivery protocol was further
evaluated in a MRI-based 2-D nose model. Figure 3a shows the
nasal airflow field, which is divided into three streams by the
inferior and middle conchae (or turbinates). The upper stream is
further split by the superior concha, with only a minor portion of
the flow stream being distributed to the olfactory region (the
uppermost location of the nasal cavity). Overall, the upper nasal
cavity receives a small fraction of the inhaled airflow, indicating
low particle transmission probability to this region. From Fig. 3a,
the streamlines that start from the anterior nostril move towards
the upper passage while those from the posterior nostril moves
towards the nasal floor (i.e. inferior meatus). It is therefore
conceivable that particles administered at the nostril tip have a
higher possibility to reach the olfactory region.
To test the electrophoretic intranasal delivery protocol, four
electrodes were arranged around the nose. The electric potentials
were set to 23 V, 28 V, 212 V, and 0 V, respectively (Fig. 3a).
The small voltage differential (3 V) in the nasal vestibule was to
provide a slight driving force toward the upper nasal cavity while
4
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Figure 2. Electric field and particle trajectories within the quadrupole geometry with three electrode voltage layouts: (a) layout 1,
(b) layout 2, and (c) layout 3.
doi:10.1371/journal.pone.0086593.g002

at the same time trying to avoid particle collisions with the
vestibule. The voltage differential increased to 8 V after the nasal
valve region to further guide particles toward the olfactory region.

The voltage differential increased to 12 V directly above the
olfactory region to attract the drug aerosols. Figure 3b displays the
resulting electric potential field. The E-field is observed to change

Figure 3. Dynamics of 2-D intranasal delivery: (a) airflow, (b) electric potential field, (c) particle trajectories with electrophoretic
forces, and (d) particle trajectories without electrophoretic forces. In the electric field, the red color represents zero voltage and the blue
color represents negative voltages.
doi:10.1371/journal.pone.0086593.g003
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from nearly 0 V at the nostrils to nearly 212 V at the olfactory
region.
Figures 3c and 3d compare the particle positions with and
without electrophoretic forces at varying instants from their release
at the nostrils. The particles considered are 0.5 mm in diameter
with a density of 1 g/cm3 and a charge number of 200. Both
airflow and particles enter the nostril at a speed of 0.1 m/s. The
particle profiles without and with electrophoretic forces appear
similar initially. The deviation becomes apparent thereafter
(0.75 s) and continues to increase till 1.5 s. Due to the increasing
upward electrophoretic force, a majority of the particles impinge
on the three nasal conchae (or turbinates), and only a small portion
of particles (,14%) reach the olfactory region (Fig. 3d). In
contrast, there is almost no deposition in the olfactory region
without electrophoretic guidance (Fig. 3c).
Based on the observation that conchae depositions are
predominately from particles that are released at the lower half
of the nostril, it is natural to conjecture that by avoiding drug
release from this region unwanted depositions in the nasal conchae
will decrease. Figure 4a shows scenarios of administering drugs
from the upper half of the nostril only (i.e., partial drug release),
which significantly reduces the deposition in the middle concha
and nearly eliminates the deposition in the inferior concha. In the
case with electrophoretic guidance, partial release delivers about
45% of the drugs to the olfactory region, while the remainder
(,55%) depositing on the superior concha (Fig. 4a). To further
reduce drug waste, we refined the drug release area so that all
particles from that area could navigate through the nasal passages
and reach the olfactory region. Figure 4b shows the particle
dynamics one second after their release from a pointed region at
the tip of the nostril. Nearly all electrophoretic-driven particles
from this region (,95%) deposit on the olfactory region. In
contrast, only 0.77% of the particles released from this region end
up in the olfactory region in the absence of electrophoretic forces.
The deposition rates of drug particles at the olfactory region
(i.e., olfactory dosage) are shown in Fig. 5 using a logarithmic
scale. From Fig. 5, applying electrophoretic forces remarkably
enhances the olfactory dosage. In this pilot 2-D study, electrophoresis-guided delivery gives rise to olfactory dosages that are two
orders of magnitude higher compared to drug deliveries without

electrophoretic forces. Furthermore, releasing drugs into the upper
half portion of the nostril (i.e., partial release) leads to an olfactory
dosage two times higher than when releasing drugs over the entire
nostril area (i.e., conventional release). The optimal release
position with electrophoretic guidance is located at the top of
nostrils, which delivers 95% drugs to the olfactory region.
Considering the extremely low olfactory delivery efficiency
(0.11–0.77%) with traditional approaches, this new protocol is
highly advantageous in developing novel devices specifically for
the nose-to-brain drug delivery.

Three-dimensional Nose Model
The rationale underlying 2-D studies is that the motion of a
particle can be largely assumed as planar and that the sideway

Figure 5. Comparison of olfactory dosages with and without
electric forces in the 2-D model on a logarithmic scale. The
olfactory dosages can be two orders of magnitude higher with applied
E-forces than without.
doi:10.1371/journal.pone.0086593.g005

Figure 4. Particle trajectories with and without electric forces: (a) partial release; (b) pointed release.
doi:10.1371/journal.pone.0086593.g004
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motions are insignificant. This is reasonable when the purpose is to
identify the appropriate operating parameters (electric potential
and mass/charge ratio) to be used in 3-D scenarios. However,
nasal airflows are fundamentally three dimensional, with significant secondary motions distributing the inhaled air/particles
within the nose in a highly heterogeneous manner. Moreover, 2-D
studies are inadequate when the electrode layout is sought to
generate a 3-D electrical field for precise particle guidance.
Figure 6 shows the diagram of the electrode layout for the
electrophoretic olfactory delivery. There are four rows of
eletrodes, with two rows positioned along the ridges of the two
nasal passges and the other two along the sides of the nose (Fig. 6).
Approporiate electric poentials are specfied in order that the
therapeutic agents administered at the nostrils can (a) escape the
nasal valve/turbinate capture and (b) deposit in the olfactory
region. Accordingly, two external force components are required:
an upward force that drives particles toward the olfactory region
by overcoming gravity and the downward drag force, and a lateral
(x-direction) force that keeps the particles from depositing on the
side walls of the conchae. The two top rows, which are negatively
charged, provide the upward force, while the two side rows
provide the lateral forces. In this study, medications are
adminsitrated only at the left nostrils, and therefore only
electrordes on the left top rows and the two side rows are used
(Table 1). Furthermore, to evaluate the influence of different
pointed release positions on olfactory dosing, a 1.5 mm-diameter
catheter located at four locations (1 mm apart) in the left nostril
will be tested (Fig. 6). The particles considered are assumed to be
monodispersed and have a diameter of 0.5 mm, a density of 1 g/
cm3, and carry 200 electric charges [13].
Detailed knowledge of aerodynamics is crucial in predicting the
behavior and fate of inhaled agents. The airflow fields and particle
dynamics in the 3-D nasal airway are shown in Fig. 7 for an
inhalation velocity of 0.1 m/s. Similar as the 2-D case, flows of
high velocity magnitude occur in the middle portion of the medial
passage, while the narrow fin-like meatus regions receive a small
fraction of the airflow. The main flow changes its direction
dramatically from the nostrils to the nasopharynx, forming a
nearly 180u curvature. A recirculation zone is observed in the
upper dorsal part of the nasopharynx as a result of sudden area
expansion in both cross-sectional and effective flow areas (Fig. 7a).
It is also observed that only the streamlines from the anterior
nostril travel to the olfactory region, which move upward prior to
the olfactory and downward after it.
For the breathing condition considered in this study (0.1 m/s), it
takes 0.6–1 seconds after administration for the particles to reach
the olfactory region (Fig. 7b). Because of the dramatic airway bend
from the nostrils to the nasopharynx, a high-concentration of
particles constantly adjust their directions following the mean
streamline curvature of inhaled airflows. Faster transport and
deeper penetration of aerosols are apparent in the medial passages
while slow-moving particles are found near the airway walls. Only
a small portion is observed to deposit in the superior meatus, with
even less particles reaching the upmost olfactory region. The

surface deposition of inhaled aerosols is accordingly highly
heterogeneous, as illustrated in the surface deposition (Fig. 8a).
A comparison of deposition patterns with and without
electrophoretic forces is illustrated in Fig. 8 for particles of
0.5 mm diameter and 200 electric charges. In both cases, 10,000
particles are released evenly over the entire area of the left nostril.
With a proper electric potential layout (Table 1), a noticeable
percentage (3.7%) of administered medications reaches the
targeted olfactory region (Fig. 8a, left panel). In contrast, the
possibility of olfactory deposition is negligible (0.06%) in absence
of electrophoretic forces (Fig. 8a, right panel).
To further increase the olfactory delivery efficiency, medications
are administered at one small point (Point B in Fig. 8b) in the
anterior nostril to help escape the nasal valve/turbinate capture.
In both cases, drug loss to the nasal valve and turbinates are
remarkably diminished. More importantly, with electrophoretic
guidance, a majority (92%) of therapeutic agents made their way
to the olfactory (red ellipse) that would have otherwise deposited in
the superior turbinate and nasopharynx (Fig. 8b, left panel vs.
right panel). A careful inspection of the deposition in the superior
turbinate (green square) in the right panel of Fig. 8b reveals that
particles are deposited at the outer side (turbinate surface) in
contrast to the inner septum wall. To reduce deposition here, a
lateral force component is needed to repel these particles from
approaching the outer wall.
The mechanism underlying the electrophoretic olfactory
delivery is illustrated in Fig. 9, which shows the deflection of
charged particles from the airflow streamlines, the electric
potential field, and the x-direction (lateral) component of the
resultant electric force. The deflection becomes apparent initially
in the region beneath the olfactory. As discussed before, it takes
0.6–1.0 s for particles to travel from the nostril to this region,
mainly due to the aerodynamic forces. After that, the upward
electrophoretic force becomes dominant, which alters the particle
trajectory and orientates them towards the olfactory. This process
is slow and can take 1–2 seconds, as indicated by the color
migration from green to red in Fig. 9a.
The external electric potential field and electrophoretic force
experienced by drug particles are shown in Figs. 9b&c. To
successfully maneuver the particles through the convoluted nasal
passage, the electric potential must vary in both magnitude and
direction along the particle path, depending on the path
deflections required to escape being captured by the nasal valve
or turbinates. In this case, particle motion can be divided into
three stages: the aerodynamically controlled stage (0–0.5 s) that
transports particles from the nostril to the superior meatus, the
second stage where both drag and electric forces are important
(0.5–1 s), and the third stage (1–2 s) where the particles are
diverted to the olfactory by electrophoretic attractions. In the
second stage, a lateral electric force is exerted on the charge
particles that points toward the septum (negative x-direction in
Fig. 9c) and helps to divert the particles from depositing onto the
turbinate.

Table 1. Electric potentials on the electrodes of top left (L) and left side (LS) rows.

Voltage (V)

1

2

3

4

5

Left (L)

0

2

2

4

24

Left Side (LS)

1

1

3

0

212

6

7

8

28

212

212

NA

NA

NA

doi:10.1371/journal.pone.0086593.t001
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Figure 6. Diagram of electrode configuration and four particle-pointed-release positions. There are four groups of electrodes in tandem,
with one group on each side of the nose and one group lining above each of the two nasal ridges. L: left; R: right; LS: left side; RS: right side.
doi:10.1371/journal.pone.0086593.g006

(local velocity and electric field). Considering these interacting
factors, it is not surprising that the olfactory dosing will exhibit a
high sensitivity to different release locations.

Figure 10 compares the predicted olfactory delivery efficiency
with and without electrophoretic forces using a logarithmic scale.
Overall, the numerical predictions in the 3-D model corroborate
with the 2-D results that electrophoretic forces can significantly
enhance olfactory delivery. With appropriate E-forces, the
olfactory deposition rates can be two orders of magnitude higher
than that without electrophoretic control. Furthermore, administering therapeutic agents at a specific location (i.e., pointed drug
release) further enhances the olfactory delivery over the conventional practice of administering drugs over the entire area of the
nostril (conventional release). It is also noted that the olfactory
delivery efficiency is highly sensitive to the pointed release position.
For a given electric field and its optimal release point (point B in
this study), the olfactory dosage decreases from 92% at point B to
75% by shifting the release position only 1 mm forward to point A,
reduces to 67% by 1 mm backward to point C, and to 41% by
2 mm backward to point D. Charged particle transport through
an airflow and electric field is a dynamic process. The trajectory of
such a particle is a result of the interplay between aerodynamic
and electric forces. Moreover, the relationship between the
electrophoretic deflection and electric potential is nonlinear
(second-order derivative in nature) and is spatially dependent

Discussion and Summary
In this pilot study, we demonstrated the feasibility of intranasal
drug delivery to the olfactory region with electrophoretic guidance
in an image-based human nose model. Effective olfactory dosing is
the crucial first step in direct nose-to-brain delivery, the feasibility
of which rests on two factors: effective dosage to the central
nervous system (CNS) and no obvious systemic side effects. In this
regard, the optimal olfactory dosage (92%) predicted in this study
appears very promising. The highest voltage applied around the
nose is only 12 V, which is safe to the human body and can be
easily achieved using a 12 V battery.
The complexity of the nasal cavity precludes effective intranasal
drug delivery. Most inhaled particles will impinge on the intranasal
walls and be filtered out of the respiratory tract. This explains how
the human nose functions as an effective filter and is considered
our first defense line. However, this same defense has for decades
baffled efforts in searching for effective methods to deliver

Figure 7. Inhalation airflow streamlines (a) and snapshots of particle transport (b) at different instants inside the nasal cavity.
doi:10.1371/journal.pone.0086593.g007
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Figure 8. Comparison of deposition patterns with and without electrophoretic forces for particles released (a) over the entire area
of the left nostril, and (b) at point B of the left nostril.
doi:10.1371/journal.pone.0086593.g008

medications via the nasal route to the lungs, olfactory epithelium,
or paranasal sinuses. Results of this study showed that, with an
appropriate electric field, a particle’s trajectory can be precisely
controlled so as not to intercept the airway surface before reaching
the olfactory region. Success of such control rests on the accurate
knowledge of two factors: (1) the original course/trajectory of

inhaled particles, and (2) the course deflection required to escape
nasal valve/turbinate filtrations. The first factor can be readily
identified with patient-specific image-CFD modeling to determine
the necessary deflections (the second factor). The amount of
deflection for a given particle depends on the concurrent actions of
electric and aerodynamic forces, which are further determined by

Figure 9. Snapshots of particle locations (a), electric potential (b) and electrophoretic force in x direction (c) in the left nasal
passage for particles released at point B.
doi:10.1371/journal.pone.0086593.g009
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challenging to guide drug particles through these passages without
surface contact loss, which requires more precise control on
particle trajectories to achieve satisfactory delivery efficiency.
Modifications to the electric potential gradients are necessary to
correct the altered particle trajectory deflections. For severely
obstructed scenarios, reduced olfactory delivery efficiencies are
expected. To remedy this setback, vasoconstrictors such as
xylometazoline should be given first to patients with rhinitis and
rhinosinusitis to alleviate the nasal inflammation before administering medications. Generally, the nasal mucus carries a negative
charge due to sodium and chloride movements across the
membrane (i.e., 25 to 230 mV for normal subjects and 240 to
280 mV for Cystic Fibrosis patients) [45]. However, the potential
effect of this charge on particle trajectories is expected to be
negligible, considering that it has a much smaller magnitude
relative to the applied electric voltages.
Limitations of this study include the assumption of steady flows,
rigid airway walls, limited electrode layouts/operating parameters,
and neglect of facial topology. In this study, special considerations
had been taken to minimize the flow effects. First, a very low
inhalation rate (0.1 L/min) was adopted to reduce the particle
inertial effect and increase the particle reaction time to electrophoretic controls. Second, this proposed delivery protocol mainly
depends on the electrophoretic forces and therefore has less
dependence on breathing conditions. Practically, the influence of
transient breathings can be further minimized by instructing the
patient to inhale steadily and by activating the drug release only
during this quasi-steady inhalation phase. Considering the nonlinear relationship between particle trajectory and electrophoretic
force, identifying the optimal values of the electric voltages is
basically an art mixed with science, necessitating numerous trials
to find the best combination. This complexity is further
compounded by the need for precise path control that navigates
the particles through the convoluted nasal passages without loss to
the wall. Facial topology may also affect the layout of electrodes.
Each limitation influences the realism of the model predictions and
should be addressed in future studies. Additionally, this study is
limited to the nose models based on one subject and therefore does
not consider the inter-subject variability. Future numerical studies
with more image-based nose models, as well as complementary
experimental studies are necessary to advance our knowledge of
the feasibility and efficiency of this new drug delivery strategy.
In conclusion, this study systematically evaluated the feasibility
and effectiveness of targeted drug delivery with electrophoretic
forces in both idealized and realistic nose models. Specifically, the
influences of electric fields and drug-release positions were
examined in controlling the particle motion toward the olfactory
region. Results of this pilot study have implications for the
development of effective intranasal drug delivery devices that
target the olfactory epithelium. Specific findings of this study are:

Figure 10. Comparison of olfactory dosages with and without
electric forces in the 3-D model on a logarithmic scale. The
olfactory dosages can be two orders of magnitude higher with applied
E-forces than without.
doi:10.1371/journal.pone.0086593.g010

the electric potential field and the instantaneous particle speed
(residence time). Accordingly, if the particle mass/charge ratio and
inhalation rate are known, the electric field required for trajectory
defection can be calculated, which can be used to calculate the
electrode layout and strength. It is noted that there should be
deflections in more than one direction to ensure effective olfactory
dosages, as shown in Fig. 1.
The novel aspect of this study is that charged nanoparticles can
be precisely controlled using appropriate electrophoretic forces.
This protocol provides multiple advantages that are lacking in
current inhaler devices. For example, electrophoresis-guided drug
particles can be contact-free from the airway wall, which
significantly reduces drug waste in the nasal valve/conchae and
increases the olfactory dosage. As a result, it has the potential to
overcome the nose-to-brain bottleneck posed by extremely low
olfactory depositions [9]. Drug particles can be free of ferric
magnetic materials, therefore minimizing side effects from metallic
accumulations [40,41]. Furthermore, electrophoresis-guided delivery does not rely on inhalation conditions, which makes it
suitable for seniors or patients with respiratory distress who have
difficulties in exercising required breathing maneuvers [42,43,44].
The proposed platform can also be easily adapted for target drug
delivery at respiratory sites other than the olfactory region by
modifying electrode layouts and voltage gradients.
Clinically, the electrophoretic guidance system is envisioned to
consist of one zero-voltage electrode positioned within the mouth
along with four rows of negative electrodes positioned outside the
nose. Each row will include multiple electrodes where different
voltages are applied to create a desired electric field in the nose. A
head brace can be used to stabilize the electrodes relative to the
head so that there is no direct contact between the electrodes and
human body. In this proposed protocol, a patient-specific imageCFD modeling is necessary to determine the required deflections.
The cost incurred by MRI scans and CFD modeling could be a
potential barrier to its applications in human population.
Inflammation of the nasal mucous membrane due to allergic
rhinitis or rhinosinusitis leads to narrowing and obstruction of the
already narrow nasal passages. It will conceivably be more
PLOS ONE | www.plosone.org

1. It is feasible to focus and guide nanoparticles with electric
voltages that are safe to the human body (,12 V).
2. Applying electrophoretic forces can significantly increase the
olfactory deposition of nanoparticles with diameters of 0.5 mm
and below.
3. Electrophoretic olfactory delivery exhibits high sensitivity to
drug release positions.
4. With appropriate electrophoretic guidance and selective drug
release, an olfactory delivery efficiency of more than 90% can
be achieved.
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